We are live on ! Find out more
GIM

Greylin Investment Management Portfolio holdings

AUM $598M
1-Year Est. Return 18.59%
This Fund
S&P 500
This Quarter Est. Return
-13.18%
1 Year Est. Return
+18.59%
3 Year Est. Return
+52.1%
5 Year Est. Return
+133.23%
10 Year Est. Return
+214.42%
AUM
$417M
AUM Growth
-$46.8M
Cap. Flow
+$82.1M
Cap. Flow %
19.68%
Top 10 Hldgs %
71.44%
Holding
87
New
11
Increased
13
Reduced
41
Closed
12

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.56M
2
GILD icon
Gilead Sciences
GILD
+$9.19M
3
USG
Usg
USG
+$4.21M
4
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$2.7M
5
IBM icon
IBM
IBM
+$2.19M

Sector Composition

Rank Sector Weight
1 Financials 38.81%
2 Energy 20.1%
3 Technology 14.87%
4 Healthcare 11.77%
5 Consumer Staples 7.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BRK.B icon
1
Berkshire Hathaway Class B
BRK.B
$1.08T
$140M 33.54%
685,513
-12,929
-2% -$2.7M
XOM icon
2
ExxonMobil
XOM
$658B
$27M 6.47%
396,185
-19,215
-5% -$1.51M
IBM icon
3
IBM
IBM
$217B
$20.5M 4.92%
189,033
-18,287
-9% -$2.19M
QCOM icon
4
Qualcomm
QCOM
$173B
$19.7M 4.72%
346,444
+8,876
+3% +$539K
BP icon
5
BP
BP
$110B
$17M 4.08%
463,427
-13,996
-3% -$559K
NXPI icon
6
NXP Semiconductors
NXPI
$56.3B
$17M 4.06%
+231,432
New +$18.3M
SLB icon
7
SLB Ltd
SLB
$79.4B
$15.7M 3.76%
435,019
+304,300
+233% +$15M
JNJ icon
8
Johnson & Johnson
JNJ
$652B
$14.4M 3.44%
111,349
-10,333
-8% -$1.44M
KHC icon
9
Kraft Heinz
KHC
$29.2B
$13.7M 3.27%
317,371
+129,382
+69% +$6.7M
UTHR icon
10
United Therapeutics
UTHR
$22.2B
$13.2M 3.15%
+120,793
New +$14M
BAC icon
11
Bank of America
BAC
$436B
$8.47M 2.03%
343,950
-10,730
-3% -$291K
MRK icon
12
Merck
MRK
$379B
$7.76M 1.86%
106,409
-135,407
-56% -$9.56M
KO icon
13
Coca-Cola
KO
$390B
$7.09M 1.7%
149,825
-17,790
-11% -$851K
TPR icon
14
Tapestry
TPR
$26B
$6.37M 1.53%
188,605
-27,545
-13% -$1.11M
GIS icon
15
General Mills
GIS
$21.5B
$5.85M 1.4%
150,258
-4,662
-3% -$197K
WFC icon
16
Wells Fargo
WFC
$258B
$5.3M 1.27%
114,981
-3,900
-3% -$200K
HD icon
17
Home Depot
HD
$336B
$5.17M 1.24%
30,114
-430
-1% -$77.1K
USG
18
DELISTED
Usg
USG
$4.73M 1.13%
110,784
-98,331
-47% -$4.21M
USB icon
19
US Bancorp
USB
$98.3B
$4.07M 0.98%
89,128
-1,900
-2% -$97.8K
COP icon
20
ConocoPhillips
COP
$159B
$4.02M 0.96%
64,415
-19,050
-23% -$1.3M
NAT icon
21
Nordic American Tanker
NAT
$1.39B
$3.68M 0.88%
1,839,920
+118,975
+7% +$310K
TEVA icon
22
Teva Pharmaceuticals
TEVA
$43.6B
$3.28M 0.79%
212,455
-24,440
-10% -$501K
RDS.A
23
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$3.01M 0.72%
51,635
+13,405
+35% +$831K
LLY icon
24
Eli Lilly
LLY
$1.06T
$2.97M 0.71%
25,640
-575
-2% -$64.2K
APA icon
25
APA Corp
APA
$14.7B
$2.85M 0.68%
108,690
+2,265
+2% +$83.5K

Similar funds

Greylin Investment Management's Q4 2018 Portfolio in Review

As of Q4 2018, Greylin Investment Management held 87 positions worth $417M, down 10% from $464M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Greylin Investment Management deployed $82.1M of net new capital in Q4 2018, opening 11 new positions and adding to 13 existing holdings. Its largest new stake was Berkshire Hathaway Class A: 200 shares worth $612K.

By sector, the portfolio is most concentrated in Financials at 39% of assets, up from 37% a quarter earlier, followed by Energy and Technology.

On the sell side, the largest reduction was Merck, an estimated $9.56M trimmed.

  • Greylin Investment Management's largest Q4 2018 buy was Berkshire Hathaway Class A: 200 shares worth $612K.
  • Greylin Investment Management added most to SLB Ltd in Q4 2018, an estimated $15M increase.
  • Greylin Investment Management's biggest Q4 2018 reduction was Merck, cutting an estimated $9.56M.
  • Greylin Investment Management fully exited Meridian Bioscience Inc in Q4 2018, selling an estimated $709K.
  • Greylin Investment Management's ten largest holdings make up 71% of its $417M portfolio in Q4 2018.
  • Greylin Investment Management opened 11 new positions and closed 12 in Q4 2018.
  • Greylin Investment Management's portfolio value fell 10% quarter-over-quarter to $417M.

Based on Greylin Investment Management's 13F filing for Q4 2018, filed 14 Jan 2019.